drugset / Trial / NCT01019473

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

NCT01019473

Phase 2 Terminated 44 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.

Timeline

Start
2009-11
Primary completion
2011-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule Oral